Anebulo Pharmaceuticals (ANEB) said Wednesday that its board of directors and a special committee of independent directors have recommended a reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500, as part of its going private transactions.
The company said the reverse stock split is intended to reduce Anebulo's stockholders enough to allow the company to terminate its registration as a US Securities and Exchange Commission reporting company.
Under the reverse stock split, the company's stockholders will receive cash in the amount of $3.50 per pre-split share in exchange for any fractional shares of post-split stock.
Shares of the company were up 73% in recent Wednesday tracing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。